4.3 Article

The role of VEGF-C staining in predicting regional metastasis in melanoma

期刊

VIRCHOWS ARCHIV
卷 453, 期 3, 页码 257-265

出版社

SPRINGER
DOI: 10.1007/s00428-008-0641-6

关键词

skin; melanoma; lymphangiogenesis; sentinel lymph node; VEGF-C; TAMs; immunohistochemistry

资金

  1. National Fund for Scientific Research-Flanders [G.0128.06]

向作者/读者索取更多资源

Sentinel lymph node status is the most important prognostic factor in primary melanoma. The number of melanoma-associated lymphatic vessels has been associated with sentinel lymph node status and survival. Vascular endothelial growth factor-C (VEGF-C) is found to promote tumour-associated lymphatic vessel growth. In many human neoplasms, VEGF-C expression in neoplastic cells or tumour-associated macrophages (TAMs) has been linked to lymphatic dissemination of tumour cells. Recent studies have suggested a correlation between VEGF-C expression in primary melanoma and the presence of lymph node metastasis. We performed VEGF-C immunohistochemical staining on melanoma tissues of 113 patients with known sentinel lymph node status. We showed that both high VEGF-C expression in melanoma cells and TAMs are positively associated with the presence of a positive sentinel lymph node. No correlation with Breslow thickness, Clark invasion level or ulceration could be detected. VEGF-C expression in melanoma cells was predictive of a shorter overall and disease-free survival, without being an independent predictor of survival. Our results confirm that VEGF-C expression in primary cutaneous melanoma plays a role in the lymphatic spread of the tumour.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Dermatology

Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis

N. Van den Berghe, E. De Keyser, R. Soenen, L. Meuleman, S. Lanssens, A. Gils, J. Lambert

BRITISH JOURNAL OF DERMATOLOGY (2020)

Article Dermatology

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)

J. L. W. Lambert, S. Segaert, P. D. Ghislain, T. Hillary, A. Nikkels, F. Willaert, J. Lambert, R. Speeckaert

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Article Dermatology

Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)

J. L. W. Lambert, S. Segaert, P. D. Ghislain, T. Hillary, A. Nikkels, F. Willaert, J. Lambert, R. Speeckaert

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Article Dermatology

Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey

Lisa Schots, Lynda Grine, Rani Soenen, Jo Lambert

Summary: This study shows that most dermatologists empirically adjust the dosage of biologics. The majority of dermatologists recognize the need for therapeutic drug monitoring (TDM), indicating the necessity for effective communication about the availability, utility, and implementation of TDM assays in daily dermatology practice.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Review Medicine, General & Internal

Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review

Jo L. W. Lambert, Sofie De Schepper, Reinhart Speeckaert

Summary: Biologics used in the treatment of Crohn's disease and ulcerative colitis can lead to various skin eruptions, especially those targeting TNF-alpha and Th17 pathway. It is important to recognize and adapt the treatment strategy accordingly to manage these adverse reactions effectively.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Biochemistry & Molecular Biology

Personalized Development of Antisense Oligonucleotides for Exon Skipping Restores Type XVII Collagen Expression in Junctional Epidermolysis Bullosa

Michael Ablinger, Thomas Lettner, Nicole Friedl, Hannah Potocki, Theresa Palmetzhofer, Ulrich Koller, Julia Illmer, Bernadette Liemberger, Stefan Hainzl, Alfred Klausegger, Manuela Reisenberger, Jo Lambert, Mireille Van Gele, Eline Desmet, Els Van Maelsaeke, Monika Wimmer, Roland Zauner, Johann W. Bauer, Verena Wally

Summary: Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is a rare disease with heterogeneous mutations, making therapy development challenging. However, the use of AON to induce exon skipping shows promise as a personalized treatment approach for this condition.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Medicine, General & Internal

Computer-Aided Assessment of Melanocytic Lesions by Means of a Mitosis Algorithm

Bart Sturm, David Creytens, Jan Smits, Ariadne H. A. G. Ooms, Erik Eijken, Eline Kurpershoek, Heidi V. N. Kuesters-Vandevelde, Carla Wauters, Willeke A. M. Blokx, Jeroen A. W. M. van der Laak

Summary: An increasing number of pathology laboratories are using whole slide imaging for routine diagnostics, which provides a pathway for the application of artificial intelligence in computer-aided diagnosis. This study applied a mitosis algorithm primarily developed for breast cancer to the diagnosis of melanocytic skin lesions and found that pathologists perform similarly with and without the aid of the algorithm in general cases. However, the algorithm improved the performance of pathologists in diagnosing nevoid melanoma cases.

DIAGNOSTICS (2022)

Article Health Care Sciences & Services

The Effects of Modified Intermittent Fasting in Psoriasis (MANGO): Protocol for a Two-Arm Pilot Randomized Controlled Open Cross-over Study

Lynda Grine, Niels Hilhorst, Nathalie Michels, Souheila Abbeddou, Stefaan De Henauw, Jo Lambert

Summary: This study aims to investigate the effects of MIF on skin, gut, and metabolic health in psoriasis patients. Through clinical and molecular research, we hope to understand the differences in psoriasis severity and gut health integrity between MIF and a regular diet, as well as how dietary lifestyles can impact the development of psoriasis.

JMIR RESEARCH PROTOCOLS (2022)

Editorial Material Dermatology

Weighing in on weight-based secukinumab dosing for psoriasis

Deepak M. W. Balak, Jo Lambert

BRITISH JOURNAL OF DERMATOLOGY (2022)

Article Dermatology

Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis

Rani Soenen, Zhigang Wang, Lynda Grine, Erwin Dreesen, Lisa Schots, Els Brouwers, Paul Declerck, Debby Thomas, Jo Lambert

Summary: This study aimed to develop and validate an immunoassay for secukinumab and determine the therapeutic window in patients with psoriasis. The results showed that secukinumab trough concentrations decreased with increasing body mass index (BMI). The minimal effective threshold was found to be 39.1 mg/L, which was associated with a high probability of optimal clinical response. Monitoring and adjusting secukinumab trough concentration to 39.1 mg/L may be a viable treatment option for suboptimal responders.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Article Medicine, General & Internal

Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice

Rani Soenen, Christophe Stove, Alessio Capobianco, Hanne De Schutter, Marie Dobbelaere, Tahmina Mahjor, Merel Follens, Jo Lambert, Lynda Grine

Summary: Therapeutic drug monitoring (TDM) of biologics, including the measurement of drug concentrations and antibodies, is a valuable tool for clinical decision making. In this study, the feasibility and perception of home microsampling for quantification of adalimumab concentrations in psoriasis patients were evaluated. The results showed that lateral flow testing (LFT) and enzyme-linked immunosorbent assay (ELISA) provided consistent measurements. The study demonstrates the potential for TDM implementation for adalimumab using rapid testing and home-based microsampling.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Dermatology

Initiating value-based healthcare in psoriasis: Proposing a value-based outcome set for daily clinical practice

Niels Timo Hilhorst, Elfie Deprez, Deepak Mukesh Wieshwaykumar Balak, Nanja Van Geel, Jan Gutermuth, Isabelle Hoorens, Jo Lydie Wilfried Lambert

Summary: This study aims to develop an actionable value-based outcome set (VOS) for evaluating psoriasis care. Through four phases of a mixed method approach, the study identified the outcomes deemed important by patients and selected suitable instruments to measure these outcomes. This VOS allows for the evaluation and improvement of current care processes, increasing value for patients.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Article Oncology

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

Melissa M. M. De Meza, Willeke A. M. Blokx, Johannes J. J. Bonenkamp, Christian U. U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. J. Van Not, Djura Piersma, Rozemarijn S. S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters

Summary: BRAF/MEK therapy and anti-PD-1 therapy have shown better recurrence-free survival in stage III melanoma patients with BRAF V600 mutations. This study aimed to compare the toxicity and survival outcomes of these therapies in daily practice. The results showed that grade >= 3 toxicity occurred in 11.5% of patients, leading to early treatment discontinuation in 71.1% of cases. At 12 months, patients treated with BRAF/MEK therapy had better progression-free survival than those treated with anti-PD-1 therapy, but this difference was no longer observed at 18 months.

CANCERS (2023)

Article Dermatology

Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative

Jan Koren, Jo L. W. Lambert, Simon F. F. Thomsen, Helen McAteer, Gabriella Fabbrocini, Valeria Corazza, Denis Jullien, Matthias Augustin, Richard B. B. Warren, Menno A. A. de Rie, Elizabeth Lazaridou, Lluis Puig, Loic Guillevin, Marius Grosser, Wolf-Henning Boehncke

Summary: By combining the perspectives of patients, clinicians, and payors, we identified multiple themes to improve the standard of care for patients with psoriasis. Through a Delphi process, consensus was reached on these themes and a set of practical 'Calls to Action' were proposed. Improving healthcare systems, patient access, quality-of-life measures, relevance and reach of guidelines, and patient education were all recognized as important factors.

DERMATOLOGY AND THERAPY (2023)

Article Oncology

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Olivier J. van Not, Thijs T. Wind, Rawa K. Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. Haanen, Ellen Kapiteijn, Manja Bloem, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Willeke A. M. Blokx, Karijn P. M. Suijkerbuijk, Rudolf S. N. Fehrmann, Geke A. P. Hospers

Summary: This study aimed to identify prognostic factors in advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors. The analysis found that the serum lactate dehydrogenase (LDH) level was the strongest clinical parameter associated with survival.

CANCERS (2023)

暂无数据